MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis
Open Access
- 9 December 2024
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 52, 102235
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancerOncogene, 2023
- Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspectiveCancer and Metastasis Reviews, 2022
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D InhibitorJournal of Medicinal Chemistry, 2021
- KRAS mutation: from undruggable to druggable in cancerSignal Transduction and Targeted Therapy, 2021
- Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancerCell Death & Disease, 2021
- Cancer burden of major cancers in China: A need for sustainable actionsCancer Communications, 2020
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacyCancer Treatment Reviews, 2019
- Emerging roles and mechanisms of FOXC2 in cancerClinica Chimica Acta, 2018
- Mutations of key driver genes in colorectal cancer progression and metastasisCancer and Metastasis Reviews, 2018
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorCell, 2018